IDH2 Mutation
3
0
0
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
6 treatments under study, led by Therapeutic Conventional Surgery
Research Leaders
9 sponsors active, led by National Cancer Institute (NCI)
Related Conditions
Often studied with 8 related conditions
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 3 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
100%
2 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (3)
Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations
Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
Research Network
Common Treatments
- Therapeutic Conventional Surgery1
- Temozolomide1
- Cytarabine Plus Daunorubicin1
- Ven Combined With Azacitidine1
- Ruxolitinib1
Active Sponsors
- National Cancer Institute (NCI)2
- National Institutes of Health (NIH)1
- Myeloproliferative Neoplasms Research Consortium1
- BeiGene1
- John Mascarenhas1
Top Investigators
Icahn School of Medicine at Mount Sinai
Ruijin Hospital
ABTC/University of Virginia
Mays Cancer Center at UT Health
ABTC/Yale University
Related Conditions
- Idh1 Mutation2
- Chronicphase Myelofibrosis1
- Acute Myeloid Leukemia1
- Recurrent Who Grade Ii Glioma1
- Recurrent Glioblastoma1